Results 71 to 80 of about 21,822 (212)

Non‐canonical PKG1 regulation in cardiovascular health and disease

British Journal of Pharmacology, EarlyView.
It is well established that the cyclic GMP‐dependent protein kinase I (PKG1) is canonically activated by cyclic guanosine monophosphate (cGMP), enabling its regulation of vascular tone, cardiac function and smooth muscle homeostasis. However, diverse non‐canonical stimuli of PKG1 have also been identified.
Jie Su, Joseph Robert Burgoyne
wiley   +1 more source

Inhibition of late sodium current prevents pathological hyperactivation of calcium/calmodulin‐dependent protein kinase IIδ in a murine model of acute doxorubicin‐related cardiotoxicity

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Doxorubicin (DOX) is a highly effective anthracycline, whose clinical application for cancer is limited by cardiotoxicity. The mechanisms underlying doxorubicin‐induced toxic cardiomyopathy (DICM) involve electrophysiological remodelling with intracellular Na+ overload because of increased late INa and hyperactivation of
Anna‐Lena Feder, Anna‐Maria Pfützenreuter, Lea Maria Funke, Maria Johanna Baier, Daniel Tarnowski, Laura Stengel, Lars Siegfried Maier, Can Martin Sag   +7 more
wiley   +1 more source

Rosemary metabolite carnosic acid opens Kv1.1 via its voltage sensor and corrects Kv1.1‐linked episodic ataxia in mice

British Journal of Pharmacology, EarlyView.
Background and Purpose Episodic ataxia type 1 (EA1) is an autosomal dominant neurological disorder caused primarily by loss‐of‐function mutations in the voltage‐gated potassium channel Kv1.1 (KCNA1). Small molecules that restore Kv1.1 activity hold promise as targeted therapies for EA1, yet current pharmacological strategies remain limited ...
Rían W. Manville, Ryan F. Yoshimura, Hanh A. Nguyen, Ruiming Zhao, Derk J. Hogenkamp, Steve A. N. Goldstein, Geoffrey W. Abbott   +6 more
wiley   +1 more source

Pharmacological preconditioning of resveratrol in ischemic / reherfusion injury: the role of nitric oxide

Кубанский научный медицинский вестник, 2015
The article presents the results of studies of the effect of distant preconditioning by creating short-term limb ischemia and pharmacologic preconditioning of resveratrol on the size of myocardial necrosis and the level of troponin I in serum after ...
L. M. Danilenko, M. V. Pokrovsky, I. A. Tatarenkova, V. V. Elagin, O. I. Bratchikov   +4 more
doaj  

Heart failure medication to prevent cancer therapy–related cardiac dysfunction: A narrative review

British Journal of Pharmacology, EarlyView.
Advances in oncological therapies have improved cancer survival but also have increased the clinical incidence of cancer therapy–related cardiac dysfunction (CTRCD), a spectrum of conditions ranging from subclinical biomarker or strain abnormalities to progressive heart failure and cardiogenic shock.
Fabian Voß, Paul Goerke, Malte Kelm, Amin Polzin   +3 more
wiley   +1 more source

Potential Mediators of Efpeglenatide's Cardiovascular Benefit: An Exploratory Analysis of the AMPLITUDE‐O Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims In the AMPLITUDE O trial, efpeglenatide reduced major cardiovascular events by 27% in 4076 individuals with Type 2 diabetes and established cardiovascular or kidney disease compared to placebo during a median follow‐up of 1.81 years. This exploratory mediation analysis evaluates the degree to which changes in measured clinical variables ...
Daniel Raaschou‐Oddershede, Christine R. Schwarz, Tanya Kovalova, Kelley R. Branch, Stefano Del Prato, Carolyn S. P. Lam, Renato D. Lopes, Richard Pratley, Julio Rosenstock, Naveed Sattar, Hertzel C. Gerstein   +10 more
wiley   +1 more source

Cirbp suppression compromises DHODH-mediated ferroptosis defense and attenuates hypothermic cardioprotection in an aged donor transplantation model

The Journal of Clinical Investigation
Hypothermia is commonly used to protect donor hearts during transplantation. However, patients transplanted with aged donor hearts still have severe myocardial injury and decreased survival rates, but the underlying mechanism remains unknown.
Yifan Zhu, Chenyu Jiang, Jian He, Chen He, Xingliang Zhou, Xu Huang, Yi Shen, Liwei Wu, Yongnan Li, Bei Feng, Yi Yan, Jun Li, Hao Zhang, Yiwei Liu   +13 more
doaj   +1 more source

Liraglutide combined with dapagliflozin treatment improves myocardial disease and endothelial dysfunction in T2DM mice

Journal of Diabetes Investigation, EarlyView.
Liraglutide combined with Dapagliflozin treatment improves myocardial disease and endothelial dysfunction in T2DM mice. Diabetic cardiomyopathy (DCM) and endothelial dysfunction were established in mice via HFD and STZ injection. The combination therapy of Liraglutide and Dapagliflozin synergistically improved metabolic parameters and attenuated ...
An‐Jun Tan, Tian‐Rong Li, Jing‐Jing Yang, Xiao‐Lu Li, Wen‐Qin Li, Jin‐Wen Yu   +5 more
wiley   +1 more source

Restoration of adaptive cardioprotection impaired by metabolic syndrome in rats by the PPARα activation

Acta Biomedica Scientifica
Background. It is known that the protective effect of adaptation and conditioning influence is weakened in animals with metabolic syndrome. Metabolic syndrome may be the basis for the failure of cardioprotection in clinical settings.The aim of the study.
N. V. Naryzhnaya, I. A. Derkachev, B. K. Kurbatov, M. A. Sirotina, M. Kilin, L. N. Maslov   +5 more
doaj   +1 more source

Glucagon-Like Peptide-1

JACC: Basic to Translational Science, 2016
Glucagon-like peptide-1-(7-36) amide (GLP-1) is a human incretin hormone responsible for the release of insulin in response to food. Pre-clinical and human physiological studies have demonstrated cardioprotection from ischemia-reperfusion injury.
Joel P. Giblett, BM, BSc, Sophie J. Clarke, BSc, David P. Dutka, MD, Stephen P. Hoole, MA, DM   +3 more
doaj   +1 more source